Large-scale clinical studies on the post-infectious impacts of SARS-CoV-2 have suggested that patients who have recovered from acute infection have increased risk for cardiometabolic syndrome-associated morbidities such as diabetes, chronic kidney disease and heart failure. Initial studies have taken the first steps towards unravelling the molecular processes that may be driving these findings, including the role of immune and inflammatory factors, but a comprehensive aetiology remains unclear. Given that cardiometabolic syndrome progression in patients with Long COVID may pose a significant global health and economic burden post pandemic, there is an emergent need to identify therapeutic targets and treatment options.
Read the rest of this article HERE.
Source: Frere, J.J., tenOever, B.R. Cardiometabolic syndrome — an emergent feature of Long COVID?. Nat Rev Immunol (2022). https://doi.org/10.1038/s41577-022-00739-8 (Full text)